Mode
Text Size
Log in / Sign up

Randomized trial finds konjac glucomannan reduces weight and cardiometabolic markers in excess weight adultsFiber Supplement Slashes Belly Fat and Heart Risk

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider konjac glucomannan as a co-adjuvant for weight and cardiometabolic risk reduction in adults with excess weight.

This is a randomized controlled trial in 40 adults with excess weight. The study tested konjac glucomannan 3 g/day for 12 weeks alongside personalized hypocaloric diets and moderate physical activity, compared to placebo with the same diet and activity.

The authors report reductions in body weight (mean -2.39 kg, 95% CI: -3.38, -1.40), BMI (mean -0.83 kg/m2, 95% CI: -1.15, -0.52), and waist circumference (mean -2.70 cm, 95% CI: -3.87, -1.53). Additional benefits with glucomannan versus placebo were seen for body fat percentage (mean -2.16%, 95% CI: -3.04, -1.28), visceral adipose tissue (mean -20.0 cm2, 95% CI: -29.2, -10.8), fat mass index (mean -0.98 kg/m2, 95% CI: -1.34, -0.62), LDL cholesterol (mean -14.1 mg/dL, 95% CI: -23.4, -4.9), atherogenic index (mean -0.50, 95% CI: -0.80, -0.21), and Framingham 10-year coronary risk (mean -0.370, 95% CI: -0.625, -0.115). Inflammatory and adipokine markers also improved, though some confidence intervals included null.

No adverse effects were reported, but tolerability and discontinuations were not detailed. The authors note the intervention reduced weight, BMI, and waist circumference irrespective of treatment, but additional benefits with glucomannan were specific to body fat, lipids, and inflammatory markers.

Limitations include a single RCT with a small sample size, which may limit certainty. Practice relevance is that konjac glucomannan may serve as a co-adjuvant for further risk reduction in adults with excess weight, pending larger confirmatory studies.

  • Konjac fiber cuts deep belly fat and bad cholesterol
  • Helps adults with excess weight and heart risks
  • Available now, but long-term effects still under study

This simple fiber could be a powerful ally in lowering heart disease risk for people carrying extra weight.

You’re eating better. You’re moving more. But the scale won’t budge — and your doctor keeps talking about cholesterol and heart risk. You’re not alone. Millions face this daily frustration. Now, a new study suggests a simple dietary fiber might help tip the scales — and not just on weight.

More than 1 in 3 adults in the U.S. has obesity. Many more carry excess weight that raises their risk for heart disease, diabetes, and stroke. These conditions don’t just shorten lives — they make daily life harder. Current treatments often fall short. Medications can have side effects. Lifestyle changes are tough to maintain. People need tools that work with real life, not against it.

The hidden fat danger

For years, we focused on total weight. But now we know: not all fat is the same. The real problem? Visceral fat — the kind wrapped around your organs. You can’t pinch it. But it pumps out harmful chemicals and fuels inflammation. This hidden fat is a major driver of heart disease and insulin resistance.

But here’s the twist: this new study didn’t just track the scale. It used advanced scans to measure that dangerous belly fat — and found something promising.

The old thinking was that fiber mainly helped you feel full. Good for appetite, maybe good for digestion — but not a major player in heart health. But this trial shows konjac glucomannan does more than fill your stomach. It appears to target the very roots of metabolic disease.

What makes this fiber different

Think of your gut like a busy city. Food is traffic. When traffic flows smoothly, everything works. But when it jams, problems build. Konjac glucomannan is like a smart traffic director. It absorbs water and swells into a gel. This slows digestion, steadies blood sugar, and sweeps away excess cholesterol.

It also feeds good gut bacteria — the kind that produce helpful chemicals. These microbes act like maintenance crews, reducing inflammation and improving gut lining strength. A stronger gut barrier means fewer toxins leak into the bloodstream — a key factor in chronic disease.

In this study, 40 adults with excess weight followed a healthy, calorie-controlled diet and light exercise. Half took 3 grams of konjac fiber daily. The other half took a placebo. Neither the participants nor the researchers knew who got what — making the results more trustworthy.

Results that go beyond weight

Both groups lost weight — about 2.4 kg (5.3 lbs) on average. That’s expected with diet and exercise. But the fiber group saw extra benefits the placebo group didn’t.

They lost significantly more body fat — especially dangerous visceral fat, down by 20 cm². That’s like shrinking a major risk factor without extra effort.

Their LDL (“bad”) cholesterol dropped by 14 mg/dL. Their atherogenic index — a marker of heart disease risk — also improved. Even their Framingham risk score fell, meaning their estimated 10-year chance of heart disease went down.

This doesn’t mean this treatment is available yet.

Wait — it’s already on shelves. Konjac glucomannan is found in some supplements and foods like shirataki noodles. But this study used a specific dose (3 grams daily) in a controlled setting. Real-world results may vary.

The fiber group also showed lower levels of C-reactive protein — a sign of less inflammation. Leptin, a hormone linked to hunger and fat storage, dropped too. This suggests the body’s metabolism may be resetting in a healthier direction.

But there’s a catch.

These benefits happened alongside diet and exercise. The fiber didn’t replace healthy habits — it boosted them. And while no side effects were reported, some people may experience bloating or gas when starting high-fiber supplements.

Why experts are paying attention

Most fiber studies are small or short-term. This one stands out: it’s triple-blind, placebo-controlled, and measured deep metabolic changes — not just weight. It shows konjac glucomannan isn’t just a digestive aid. It may actively improve markers tied to long-term health.

Researchers stress it’s not a shortcut. But for people struggling to reduce heart risk, it could be a practical, low-cost addition to proven strategies.

If you’re considering this fiber, talk to your doctor first. It may interact with medications or require adjustments in how you take it — like drinking plenty of water to avoid blockages.

Not all supplements are equal

The supplement market is unregulated. Products may not contain what they claim. Look for third-party tested brands. Start with a low dose to see how your body responds.

The study only lasted 12 weeks. We don’t yet know if these benefits last over time. Larger, longer trials are needed — especially in diverse populations.

This trial adds strong evidence that certain fibers can do more than we thought. Future studies may explore higher doses, different groups, or combinations with other therapies. For now, konjac glucomannan offers a promising, accessible tool — but one best used as part of a broader plan for health.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Obesity and related cardiometabolic diseases pose significant global health challenges. Konjac glucomannan, a soluble dietary fiber, has shown promise in managing these conditions. However, rigorous studies are necessary to establish its benefits on human health. We designed a parallel-arm, triple-blind, placebo-controlled RCT to test the effects of glucomannan (3 g/day, 12 weeks) on body weight and composition, lipid profile, glucose metabolism, inflammation, adipokines, intestinal permeability, gut microbiota, and fecal metabolites in 40 adults. Participants were randomly assigned to either the glucomannan or placebo group, with both groups adhering to personalized hypocaloric diets and moderate physical activity. Outcomes were analyzed as intention-to-treat using linear mixed-effect models. Irrespective of the treatment, our intervention reduced body weight (mean: -2.39 kg; 95% CI: -3.38, -1.40), BMI (-0.83 kg/m2; -1.15, -0.52), and waist (-2.70 cm; -3.87, -1.53). Glucomannan promoted additional benefits not obtained with the placebo, reducing body fat measured by DEXA (body fat%: -2.16%; -3.04, -1.28; VAT: -20.0 cm2; -29.2, -10.8; FMI: -0.98 kg/m2; -1.34, -0.62), LDL (-14.1 mg/dL; -23.4, -4.9), and the atherogenic index (-0.50; -0.80, -0.21). It also diminished the Framingham score of 10-year risk of coronary heart disease (-0.370; -0.625, -0.115), C reactive protein (-1.01 mg/L; -2.18, 0.15), leptin (-2.06 ng/mL; -4.48, 0.365), and leptin/adiponectin (-0.282; -0.603, 0.040). The two treatments had similar intakes, physical activity, and adherence to the intervention. There were no adverse effects. This intervention fostered health benefits in a population at high risk of cardiometabolic diseases. Konjac glucomannan was an effective co-adjuvant for further reducing risk factors.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.